Heartflow, Inc. (HTFL) Covered Calls

HeartFlow, Inc. is a medical technology company that utilizes AI and computational fluid dynamics to provide non-invasive diagnostic solutions for coronary artery disease (CAD). Its flagship platform creates personalized 3D heart models from standard coronary CT scans, enabling clinicians to assess blood flow and plaque composition to guide precise treatment planning.

You can sell covered calls on Heartflow, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for HTFL (prices last updated Tue 10:55 AM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

HeartFlow, Inc. (HTFL) is a commercial-stage leader in precision cardiovascular care. By pioneering the use of artificial intelligence and advanced fluid dynamics, the company offers clinicians an actionable, non-invasive alternative to traditional diagnostic methods for coronary artery disease (CAD). The HeartFlow Platform transforms routine coronary computed tomography angiography (CCTA) scans into detailed 3D representations of a patient's heart, allowing for the precise measurement of blood flow and identification of lesion-specific physiology.

The company’s primary offering, the HeartFlow FFRCT Analysis, provides a functional assessment of coronary stenoses. Additionally, HeartFlow Plaque Analysis uses AI-driven tools to quantify plaque burden and composition, helping physicians predict risk and tailor long-term treatment strategies. By bridging the gap between anatomical imaging and functional assessment, HeartFlow aims to reduce the need for unnecessary invasive procedures while improving diagnostic accuracy for millions of patients worldwide.

Competitive Landscape

HeartFlow operates in the highly specialized and competitive health information services sector. It faces competition from large, diversified medical device and imaging manufacturers, including Solventum (the healthcare spin-off of 3M) and GE HealthCare, both of which provide advanced imaging hardware and software diagnostic suites. Other notable competitors in the AI-driven diagnostics and cardiac health space include Guardant Health, which focuses on oncology, and Encompass Health, which competes in the broader post-acute care and rehabilitation sector.

The company’s competitive moat is built on its extensive proprietary database—derived from over 100 million annotated CCTA scans—which powers its AI-driven analysis. While smaller, more agile firms and private entities continue to enter the digital cardiology space, HeartFlow differentiates itself through deep integration into clinical workflows and strong validation from the American College of Cardiology and American Heart Association guidelines.

Strategic Outlook and Innovation

HeartFlow’s strategic roadmap focuses on scaling the adoption of its plaque analysis tools and expanding its geographic footprint in key markets like Europe and Japan. The company is actively working to integrate its diagnostic insights directly into clinical EHR (Electronic Health Record) systems to streamline the path from imaging to treatment. As payor coverage for AI-driven plaque analysis continues to expand in the United States, the company is shifting its focus toward driving consistent, system-level cost savings for healthcare providers.

Innovation at the company is centered on the "agentic" interpretation of cardiac data. HeartFlow is developing next-generation AI models capable of automatically flagging high-risk patient markers in real-time, effectively serving as an early-warning system for clinicians before symptoms even manifest. By layering predictive analytics onto its existing 3D modeling platform, HeartFlow aims to transition from a diagnostic aid to a foundational intelligence layer for chronic cardiovascular disease management.

Want more examples? HTEC Covered Calls | HTGC Covered Calls